Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | S100B | P04271 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7212314 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CYP3A4S1PR1TSHRTHRA | |
| SCHEMBL15127573 | 0.85 | S1PR1 (0.57) | ALDH1A1CYP3A4S1PR1CNR2ENPP2 | |
| SCHEMBL8194795 | 0.83 | ALDH1A1 (0.59) | ALDH1A1CYP3A4S1PR1TSHRTHRA | |
| SCHEMBL3385658 | 0.83 | ALDH1A1 (0.59) | ALDH1A1CYP3A4S1PR1TSHRTHRA | |
| SCHEMBL15014146 | 0.82 | S1PR1 (0.46) | ALDH1A1CYP3A4S1PR1TSHRENPP2 | |
| SCHEMBL4663824 | 0.82 | S1PR1 (0.48) | ALDH1A1CYP3A4S1PR1CNR2ENPP2 | |
| SCHEMBL1574035 | 0.80 | ALDH1A1 (0.71) | ALDH1A1CYP3A4S1PR1TSHRTHRB | |
| SCHEMBL8126760 | 0.80 | ALDH1A1 (0.55) | ALDH1A1CYP3A4S1PR1TSHRTHRA | |
| SCHEMBL7672423 | 0.80 | ALDH1A1 (0.55) | ALDH1A1CYP3A4S1PR1TSHRTHRA | |
| SCHEMBL13778840 | 0.80 | ALDH1A1 (0.55) | ALDH1A1CYP3A4S1PR1TSHRTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340673-B1 | Blue dye compound, blue resin composition for color filter containing same and color filtering using same | KYUNG-IN SYNTHETIC CO., LTD. (KR) | 2016-05-17 | — | — | US | disclosed |
| US-20160122545-A1 | BLUE DYE COMPOUND, BLUE RESIN COMPOSITION FOR COLOR FILTER CONTAINING SAME AND COLOR FILTER USING SAME | KYUNG-IN SYNTHETIC CO., LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| US-5538970-A | Treatment of cancer with imidazo-1,2-pyridazin compounds | GLAXO WELLCOME INC. (US) | 1996-07-23 | — | — | US | disclosed |
| US-5447956-A | Anticarcinogenic agents | BURROUGHS WELLCOME CO. (US) | 1995-09-05 | — | — | US | disclosed |
| US-5380759-A | Methyl N-[6-(3,4,5-trimethoxybenzloxy)imidazo[1,2-b]pyridazin-2-zyl]carbamate used to treat leukemia | BURROUGHS WELLCOME CO. (US) | 1995-01-10 | — | — | US | disclosed |
| US-5371219-A | Antitumor agents | BURROUGHS WELLCOME CO. (US) | 1994-12-06 | — | — | US | disclosed |
| EP-0305093-B1 | Imidazo(1,2-b)pyridazine derivatives | WELLCOME FOUND (GB) | 1994-04-06 | — | — | EP | disclosed |
| US-5091531-A | Antitumor agents | BURROUGHS WELLCOME CO. (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0305093-A1 | Imidazo(1,2-b)pyridazine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-03-01 | — | — | EP | disclosed |
| US-3979429-A | DISPERSE DYES | SANDOZ LTD. (CH) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | ALDH1A1 617/4885CYP3A4 1945/4885S1PR1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.